EAST Search History

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	3870	((544/336) or (514/338) or (546/271.7) or (546/277.1) or (514/338) or (546/275.7) or (544/353) or (514/338)).CCLS.	US-PGPUB; USPAT	OR	OFF	2007/11/13 10:54
L2	245	1 and cancer and urea	US-PGPUB; USPAT	OR	OFF	2007/11/13 10:54

C:\Documents and Settings\brobinson1\My Documents\stnweb\Queries\asdfdsa.str





chain nodes :
1 2 3 4 5 6 7 8 9 10
chain bonds :
1-2 2-3 3-4 3-5 5-6 6-7 7-8 8-9 9-10
exact/norm bonds :
1-2 2-3 3-4 3-5 5-6 6-7 7-8 8-9 9-10

Match level :
1:Atom 2:CLASS 3:CLASS 4:CLASS 5:CLASS 6:Atom 7:CLASS 8:Atom 9:CLASS 10:CLASS
Generic attributes :
1:
Type of Ring System : Polycyclic
8:
Saturation : Unsaturated

Element Count :
Node 8: Limited
C,C5
N,N1

10788426

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssspta1612bxr

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page for STN Seminar Schedule - N. America
NEWS 2	JUL 02	LMEDLINE coverage updated
NEWS 3	JUL 02	SCISEARCH enhanced with complete author names
NEWS 4	JUL 02	CHEMCATS accession numbers revised
NEWS 5	JUL 02	CA/CAplus enhanced with utility model patents from China
NEWS 6	JUL 16	CAplus enhanced with French and German abstracts
NEWS 7	JUL 18	CA/CAplus patent coverage enhanced
NEWS 8	JUL 26	USPATFULL/USPAT2 enhanced with IPC reclassification
NEWS 9	JUL 30	USGENE now available on STN
NEWS 10	AUG 06	CAS REGISTRY enhanced with new experimental property tags
NEWS 11	AUG 06	FSTA enhanced with new thesaurus edition
NEWS 12	AUG 13	CA/CAplus enhanced with additional kind codes for granted patents
NEWS 13	AUG 20	CA/CAplus enhanced with CAS indexing in pre-1907 records
NEWS 14	AUG 27	Full-text patent databases enhanced with predefined patent family display formats from INPADOCDB
NEWS 15	AUG 27	USPATOLD now available on STN
NEWS 16	AUG 28	CAS REGISTRY enhanced with additional experimental spectral property data
NEWS 17	SEP 07	STN AnaVist, Version 2.0, now available with Derwent World Patents Index
NEWS 18	SEP 13	FORIS renamed to SOFIS
NEWS 19	SEP 13	INPADOCDB enhanced with monthly SDI frequency
NEWS 20	SEP 17	CA/CAplus enhanced with printed CA page images from 1967-1998
NEWS 21	SEP 17	CAplus coverage extended to include traditional medicine patents
NEWS 22	SEP 24	EMBASE, EMBAL, and LEMBASE reloaded with enhancements
NEWS 23	OCT 02	CA/CAplus enhanced with pre-1907 records from Chemisches Zentralblatt
NEWS 24	OCT 19	BEILSTEIN updated with new compounds

NEWS EXPRESS 19 SEPTEMBER 2007: CURRENT WINDOWS VERSION IS V8.2, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 19 SEPTEMBER 2007.

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS LOGIN	Welcome Banner and News Items
NEWS IPC8	For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

Updated Search

10788426

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 10:22:25 ON 13 NOV 2007

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 10:22:34 ON 13 NOV 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 12 NOV 2007 HIGHEST RN 953132-99-5
DICTIONARY FILE UPDATES: 12 NOV 2007 HIGHEST RN 953132-99-5

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 29, 2007

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Documents and Settings\brobinson1\My Documents\stnweb\Queries\asdfdsa.str

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR
*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

Structure attributes must be viewed using STN Express query preparation.

=> s l1
SAMPLE SEARCH INITIATED 10:25:37 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 34918 TO ITERATE

5.7% PROCESSED 2000 ITERATIONS 0 ANSWERS

Updated Search

10788426

INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 687191 TO 709529
PROJECTED ANSWERS: 0 TO 0

L2 0 SEA SSS SAM L1

=> s l1 full
THE ESTIMATED SEARCH COST FOR FILE 'REGISTRY' IS 171.65 U.S. DOLLARS
DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N or END:y
FULL SEARCH INITIATED 10:25:41 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 700701 TO ITERATE

100.0% PROCESSED 700701 ITERATIONS 3 ANSWERS
SEARCH TIME: 00.00.12

L3 3 SEA SSS FUL L1

=> file hcaplus
COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL SESSION
FULL ESTIMATED COST 174.35 174.56

FILE 'HCAPLUS' ENTERED AT 10:25:56 ON 13 NOV 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 13 Nov 2007 VOL 147 ISS 21
FILE LAST UPDATED: 12 Nov 2007 (20071112/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l3
L4 2 L3

=> d l4, ibib abs hitstr, 1-2

L4 ANSWER 1 OF 2 HCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2002:591913 HCAPLUS
DOCUMENT NUMBER: 137:150215
TITLE: Cdk4 and/or Cdk6 inhibitors with biaryl ureas and

Updated Search

10788426

their salts as antitumor agents

INVENTOR(S): Hatayama, Satoshi; Hayashi, Kyoko; Honma, Mitsuki; Takahashi, Ikuko

PATENT ASSIGNEE(S): Banyu Pharmaceutical Co., Ltd., Japan

SOURCE: Jpn. Kokai Tokkyo Koho, 194 pp.
CODEN: JKXXAF

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2002220338	A	20020809	JP 2001-18755	20010126
PRIORITY APPLN. INFO.:			JP 2001-18755	20010126

OTHER SOURCE(S): MARPAT 137:150215

GI



I

AB This invention relates to the general structures (I; Ar = N-containing hetero aromatic ring, X, Z = C, etc.; Y = CO, etc.; R1-R5 = H, etc.) and their salts as Cdk4 and/or Cdk6 inhibitors. I have antiproliferative effects on cancer cells and are potential antitumor agents. Formulation examples of I capsules, tablets, and injections were given.

IT 322685-53-0 445430-92-2
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(Cdk4 and/or Cdk6 inhibitors with biaryl ureas and their salts as antitumor agents)

RN 322685-53-0 HCAPLUS

CN 3,4'-Bipyridine, 1-acetyl-1,2,5,6-tetrahydro-2'-[[[(2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl)amino]carbonyl]amino]- (9CI) (CA INDEX NAME)

Updated Search

10788426



RN 445430-92-2 HCAPLUS
CN Urea, N-(1'-formyl-1',2',3',6'-tetrahydro[4,4'-bipyridin]-2-yl)-N'-(2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl)- (CA INDEX NAME)



L4 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2001:78363 HCAPLUS
DOCUMENT NUMBER: 134:147614
TITLE: Preparation of N,N'-biarylurea derivatives as inhibitors of cyclin-dependent kinases (Cdk4 and Cdk6)
INVENTOR(S): Hayama, Takashi; Hayashi, Kyoko; Honma, Mitsutaka; Takahashi, Ikuko
PATENT ASSIGNEE(S): Banyu Pharmaceutical Co., Ltd., Japan
SOURCE: PCT Int. Appl., 460 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

Updated Search

10788426

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001007411	A1	20010201	WO 2000-JP4991	20000726
W: AE, AG, AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CR, CU, CZ, DM, DZ, EE, GD, GE, HR, HU, ID, IL, IN, IS, KG, KR, KZ, LC, LK, LR, LT, LV, MA, MD, MG, MK, MN, MX, MZ, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TR, TT, UA, US, UZ, VN, YU, ZA				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2380389	A1	20010201	CA 2000-2380389	20000726
JP 2001106673	A	20010417	JP 2000-274175	20000726
EP 1199306	A1	20020424	EP 2000-949909	20000726
EP 1199306	B1	20051207		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
EP 1557168	A2	20050727	EP 2005-101402	20000726
EP 1557168	A3	20070523		
R: DE, ES, FR, GB, IT				
ES 2251395	T3	20060501	ES 2000-949909	20000726
US 6958333	B1	20051025	US 2002-31795	20020402
US 2007027147	A1	20070201	US 2004-2422	20041203
PRIORITY APPLN. INFO.:			JP 1999-211384	A 19990726
			EP 2000-949909	A3 20000726
			WO 2000-JP4991	W 20000726
			US 2002-31795	A3 20020402

OTHER SOURCE(S): MARPAT 134:147614

GI



I



II

AB N-(hetero)aryl-N'-heterocyclylurea derivs. represented by general formula (I) [wherein Ar represents a nitrogenous heterocyclic aromatic group such as (un)substituted pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, pyrazolyl, pyrrolyl, imidazolyl, indolyl, isoindolyl, quinolyl, isoquinolyl, benzothiazolyl, or

Updated Search

benzoxazolyl; X and Z each represents C or N or together with R1 or R2 and/or R3 represent CH or N; Y represents CO, SO, or SO2; R1 represents hydrogen, (un)substituted lower alkyl, Y3-W2-Y4-R5, etc.; wherein R5 = H, (un)substituted lower alkyl, lower alkenyl, lower alkynyl, lower cycloalkyl, aryl, imidazolyl, isoxazolyl, isoquinolyl, isoindolyl, indazolyl, indolyl, indolidinyl, isothiazolyl, ethylenedioxyphenyl, oxazolyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, pyrazolyl, quinoxalinyl, quinolyl, etc.; W2 = ingle bond, O, S, SO, SO2, N-(un)substituted NH, SO2NH, NHSO2NH, NHSO2, CONH, NHCO, NHCONH, NHCO2, etc.; Y3, Y4 = single bond, linear or branched lower alkylene; R2 and R3 each represents hydrogen, lower alkyl or alkoxy, or Y3-W2-Y4-R5 (Y3, W2, Y4, R5 = same as above), or one of R2 and R3 together with R1 and X forms cyclohexane, cyclopentane, piperidine, 3,4,5,6-tetrahydro-1,3-oxazine, tetrahydrothiopyran, pyrrolidine, tetrahydrothiofuran, oxazolidine ring, etc.; R4 and R5 represent H, halo, OH, amino, or Y3-W2-Y4-R5 (Y3, W2, Y4, R5 = same as above)] or salts thereof are prepared The compds. (e.g. II) have a remarkable proliferation-inhibitory effect on tumor cells. A Cdk4 and/or Cdk6 inhibitor for use in the therapy of malignant tumor can hence be provided. II showed IC50 of 0.061 and 0.019 μM against cyclin-D1-Cdk4 and cyclin-D2-Cdk4, resp., vs. 0.36 and 0.056 μM, resp., for (±)-flavopiridol, and inhibited the proliferation of HCT116 and MKN-1 cells with IC50 of 0.013 and 0.10 μM, resp., vs. 0.15 and 0.87 μM, resp., for (±)-flavopiridol. Pharmaceutical formulations containing I were prepared

IT 322685-53-0P 322685-55-2P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of N-(hetero)aryl-N'-heterocyclylurea derivs. as inhibitors of cyclin-dependent kinases (Cdk4 and Cdk6) and antitumor agents)

RN 322685-53-0 HCAPLUS
CN 3,4'-Bipyridine, 1-acetyl-1,2,5,6-tetrahydro-2'-[[[(2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl)amino]carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 322685-55-2 HCAPLUS
CN 4,4'-Bipyridine, 1-acetyl-1,2,3,6-tetrahydro-2'-[[[(2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl)amino]carbonyl]amino]- (9CI) (CA INDEX NAME)

Updated Search

10788426



REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> file caold

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	13.14	187.70

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-1.56	-1.56

FILE 'CAOLD' ENTERED AT 10:26:12 ON 13 NOV 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907-1966
FILE LAST UPDATED: 01 May 1997 (19970501/UP)

This file contains CAS Registry Numbers for easy and accurate substance identification. Title keywords, authors, patent assignees, and patent information, e.g., patent numbers, are now searchable from 1907-1966. TIFF images of CA abstracts printed between 1907-1966 are available in the PAGE display formats.

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file supports REGlstRY for direct browsing and searching of all substance data from the REGISTRY file. Enter HELP FIRST for more information.

=> d his

(FILE 'HOME' ENTERED AT 10:22:25 ON 13 NOV 2007)

FILE 'REGISTRY' ENTERED AT 10:22:34 ON 13 NOV 2007

Updated Search

10788426

```
L1              STRUCTURE UPLOADED
L2            0 S L1
L3            3 S L1 FULL

     FILE 'HCAPLUS' ENTERED AT 10:25:56 ON 13 NOV 2007
L4            2 S L3

     FILE 'CAOLD' ENTERED AT 10:26:12 ON 13 NOV 2007

=> s l3
L5            0 L3

=> file hcaplus
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST.                                    0.45     188.15

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                       ENTRY    SESSION
CA SUBSCRIBER PRICE                                     0.00      -1.56

FILE 'HCAPLUS' ENTERED AT 10:26:24 ON 13 NOV 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
the American Chemical Society and is provided to assist you in searching
databases on STN.  Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 13 Nov 2007  VOL 147 ISS 21
FILE LAST UPDATED: 12 Nov 2007  (20071112/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

 This file contains CAS Registry Numbers for easy and accurate
 substance identification.

=> d his

     (FILE 'HOME' ENTERED AT 10:22:25 ON 13 NOV 2007)

     FILE 'REGISTRY' ENTERED AT 10:22:34 ON 13 NOV 2007
L1              STRUCTURE UPLOADED
L2            0 S L1
L3            3 S L1 FULL

     FILE 'HCAPLUS' ENTERED AT 10:25:56 ON 13 NOV 2007
L4            2 S L3

     FILE 'CAOLD' ENTERED AT 10:26:12 ON 13 NOV 2007
L5            0 S L3
```

Updated Search

10788426

FILE 'HCAPLUS' ENTERED AT 10:26:24 ON 13 NOV 2007

=> s dumas, j?/au and boyer, s?/au and verma, s?/au and adnane, l?/au and chen, y?/au and lee, w?/au and phillips, b?/au and smith, r?/au and scott, w?/au and burke, j?/au and chen, z?/au

766	DUMAS, J?/AU
325	BOYER, S?/AU
1697	VERMA, S?/AU
10	ADNANE, L?/AU
47778	CHEN, Y?/AU
13759	LEE, W?/AU
1030	PHILLIPS, B?/AU
15581	SMITH, R?/AU
2111	SCOTT, W?/AU
2095	BURKE, J?/AU
25681	CHEN, Z?/AU
L6 1	DUMAS, J?/AU AND BOYER, S?/AU AND VERMA, S?/AU AND ADNANE, L?/AU AND CHEN, Y?/AU AND LEE, W?/AU AND PHILLIPS, B?/AU AND SMITH, R?/AU AND SCOTT, W?/AU AND BURKE, J?/AU AND CHEN, Z?/AU

=> d l6, ibib abs hitstr, 1

L6 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2004:756711 HCAPLUS
DOCUMENT NUMBER: 141:277641
TITLE: Preparation of bicyclic (hetero)aryl- and pyridine-containing diaryl ureas as Raf kinase and angiogenesis inhibitors useful in the treatment of cancer and other disorders
INVENTOR(S): Dumas, Jacques; Boyer, Stephen; Verma, Sharad; Adnane, Lila; Chen, Yuanwei; Lee, Wendy; Phillips, Barton; Smith, Roger A.; Scott, William J.; Burke, Jennifer; Chen, Jianqing; Chen, Zhi; Fan, Jianmei; Miranda, Karl; Raudenbush, Brian; Redman, Aniko; Shao, Jianxing; Su, Ning; Wang, Gan; Yi, Lin; Zhu, Qingming
PATENT ASSIGNEE(S): Bayer Pharmaceuticals Corporation, USA
SOURCE: PCT Int. Appl., 162 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004078748	A2	20040916	WO 2004-US6287	20040301
WO 2004078748	A3	20041111		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2516931	A1	20040916	CA 2004-2516931	20040301

Updated Search

10788426

EP 1608639	A2	20051228	EP 2004-716166		20040301
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK					
JP 2006519265	T	20060824	JP 2006-508978		20040301
MX 2005PA09104	A	20060531	MX 2005-PA9104		20050826
PRIORITY APPLN. INFO.:			US 2003-450348P	P	20030228
			WO 2004-US6287	W	20040301

OTHER SOURCE(S): MARPAT 141:277641

GI



I



II

AB Title compds. I [wherein A = benzimidazolyl, 2,3-dihydro-1H-indolyl, 2,3-dihydro-1H-indenyl, 1H- or 2H-indazolyl, 1,3-benzodioxin-6-yl, quinoxalinyl, etc.; B = (un)substituted Ph, naphthyl, pyridinyl, quinolinyl; L = (CH2)m-D-(CH2)n; m, n = independently 0-4; D = O, C(:O), NH and derivs., NHCO and derivs., S, CONH and derivs.; M = (un)substituted pyridine ring; Q = C(:O)H and derivs., CO2H and derivs., CONH2 and derivs.; and their pharmaceutically acceptable salts, prodrugs, and metabolites] were prepared as Raf kinase inhibitors for treating hyper-proliferative and angiogenesis disorders, alone or in combination with cytotoxic therapies. For example, urea II was prepared from 4-(4-Amino-3-fluorophenoxy)-N-methylpyridine-2-carboxamide (preparation given), triphosgene, 2-aminoquinoxaline, in the presence of DIPEA/anhydrous DMF at 75°. Selected I showed 80% inhibition of c-Raf kinase at 1 μM. Thus, I are useful for treating cancer and other Raf kinase-mediated diseases.

Updated Search